EFFICACY OF 10 DAYS HIGH-DOSE AND DOUBLE-DOSE RABEPRAZOLE-BASED CONCOMITANT THERAPY FOR HELICOBACTER PYLORI ERADICATION AMONG LEBANESE POPULATION: A PILOT RANDOMIZED CONTROLLED TRIAL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

LBCTR

Registry ID

LBCTR2025075755

Enrollment

Registered

2025-08-14

Start date

2023-02-01

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The study focused on Helicobacter pylori (H. pylori) infection, a bacterial infection of the stomach lining that can lead to chronic gastritis, peptic ulcers, and is associated with gastric cancer and MALT lymphoma if left untreated. gastroduodenitis, GERD, Helicobacter pylori

Interventions

Helicobacter pylori, proton pump inhibitor (PPI), eradication rate, concomitant therapy, randomized controlled trial, rabeprazole.

Concomitant therapy (a combination of antibiotics with a proton pump inhibitor) was used in all groups, but with different PPI dosing and duration: Group A: 14-day concomitant therapy with rabeprazol

This randomized controlled trial included 120 patients with confirmed H. pylori infection, of whom 101 were analyzed. The study aimed to optimize PPI dosing and reduce antibiotic duration without comp

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Adult patients with documented Helicobacter pylori infection confirmed by upper gastrointestinal endoscopy. Patients treated and followed at Notre Dame des Secours University Hospital (Byblos, Lebanon) between February 2023 and December 2023. Patients who consented to participate.

Exclusion criteria

Exclusion criteria: Pregnant or nursing women. Presence of malignancy or gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Allergy or contraindication to any study medication. Active upper gastrointestinal bleeding. History of gastric surgery. Recent use of PPIs or antibiotics (before enrollment). Celiac disease. Previous H. pylori treatment. Refusal to give consent.

Design outcomes

Primary

Measure	Time frame
Name: H. pylori eradication rate;Timepoints: 6 weeks after completing treatment;Measure: Urea breath test (UBT) result (negative = successful eradication, positive = treatment failure)	—

Secondary

Measure	Time frame
Name: Treatment compliance;Timepoints: During treatment (Days 1–10 or 1–14, depending on group);Measure: Patient self-reporting and pill count to assess adherence to the prescribed regimen;Name: Incidence of adverse effects;Timepoints: During treatment and at follow-up (6 weeks);Measure: Patient-reported symptoms (e.g., nausea, diarrhea, abdominal pain) and clinical assessment;Name: Symptom improvement (e.g., dyspepsia, heartburn);Timepoints: Baseline and 6 weeks post-treatment;Measure: Standardized symptom questionnaires or scoring systems (e.g., Likert scale or visual analog scale);Name: Antibiotic resistance patterns (if tested);Timepoints: Baseline (pre-treatment);Measure: Microbial culture and sensitivity testing (if available) to assess resistance to clarithromycin, amoxicillin, or metronidazole;Name: Cost-effectiveness analysis (if applicable);Timepoints: Post-treatment;Measure: Comparison of treatment costs (medication, follow-up tests) vs. efficacy rates among groups	—

Measure

Time frame

Name: Treatment compliance;Timepoints: During treatment (Days 1–10 or 1–14, depending on group);Measure: Patient self-reporting and pill count to assess adherence to the prescribed regimen;Name: Incidence of adverse effects;Timepoints: During treatment and at follow-up (6 weeks);Measure: Patient-reported symptoms (e.g., nausea, diarrhea, abdominal pain) and clinical assessment;Name: Symptom improvement (e.g., dyspepsia, heartburn);Timepoints: Baseline and 6 weeks post-treatment;Measure: Standardized symptom questionnaires or scoring systems (e.g., Likert scale or visual analog scale);Name: Antibiotic resistance patterns (if tested);Timepoints: Baseline (pre-treatment);Measure: Microbial culture and sensitivity testing (if available) to assess resistance to clarithromycin, amoxicillin, or metronidazole;Name: Cost-effectiveness analysis (if applicable);Timepoints: Post-treatment;Measure: Comparison of treatment costs (medication, follow-up tests) vs. efficacy rates among groups

—

Countries

Lebanon

Contacts

Public Contactmarc elias

USEK

marc_elias@live.com70445079

Outcome results

None listed

Source: LBCTR (via WHO ICTRP) · Data processed: Feb 7, 2026